Table 3:
Vasorelaxation in aorta and SMA in ten-week-old offspring.
Vessel test |
Paramet er |
Male | Female | p-value | ||||
---|---|---|---|---|---|---|---|---|
CON (n=7) |
SILD (n=10) |
CON (n=7) |
SILD (n=10) |
Treatment | Sex | Treatment * sex |
||
Aorta Ach | Emax, % | 90.5 ± 2.7 | 90.1 ± 3.4 | 92.6 ± 2.2 | 93.8 ± 2.9 | 0.90 | 0.34 | 0.80 |
logEC50, M | −6.9 ± 0.4 | −6.8 ± 0.6 | −6.9 ± 0.5 | −6.5 ± 0.3 | 0.61 | 0.72 | 0.80 | |
AUC | 232 ± 29 | 247 ± 49 | 266 ± 27 | 216 ± 24 | 0.61 | 0.98 | 0.35 | |
Aorta SNP | Emax | 97.4 ± 1.2 | 98.3 ± 3.2 | 90.7 ± 3.4 | 98.9 ± 2.1 | 0.12 | 0.28 | 0.21 |
logEC50, M | −8.1 ± 0.3 | −7.9 ± 0.4 | −8.2 ± 0.3 | −8.3 ± 0.2 | 0.84 | 0.40 | 0.60 | |
AUC | 344 ± 27 | 351 ± 33 | 347 ± 25 | 372 ± 17 | 0.55 | 0.66 | 0.74 | |
SMAAch | Emax, % | 101.7 ± 6.0 | 99.3 ± 3.0 | 103.0 ± 2.3 | 100.5 ± 0.8 | 0.48 | 0.71 | 0.99 |
logEC50, M | −8.0 ± 0.2 | −9.3 ± 0.4 | −7.6 ± 0.5 | −8.2 ± 0.3 | 0.01 | 0.06 | 0.42 | |
AUC | 345 ± 20 | 449 ± 25 | 355 ± 35 | 365 ± 23 | 0.04 | 0.19 | 0.09 | |
SMASNP | Emax, % | 99.8 ± 0.3 | 100.0 ± 0.7 | 100.6 ± 2.8 | 96.2 ± 3.3 | 0.38 | 0.52 | 0.33 |
logEC50, M | −7.9 ± 0.2 | −8.9 ± 0.5 | −8.5 ± 0.4 | −8.2 ± 0.1 | 0.31 | 0.79 | 0.09 | |
AUC | 358 ± 14 | 415 ± 32 | 410 ± 25 | 344 ± 8 | 0.87 | 0.71 | 0.03 |
Ach, acetylcholine; AUC, area under the curve; CON, control; Emax, maximum relaxation at 10−4.5; logEC50, sensitivity in M; SILD, sildenafil; SMA, third-order (small) mesenteric arteries; SNP, sodium nitroprusside. Mean ± s.e.m.